A simple method to measure CLOCK-BMAL1 DNA binding activity in tissue and cell extracts

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.12688/f1000research.11685.2

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491982

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
METHOD ARTICLE

A simple method to measure CLOCK-BMAL1 DNA binding activity in tissue and cell extracts [version 2; referees: 3 approved]

Maud Gillessen1,2*, Pieter Bas Kwak1*, Alfred Tamayo1

1Department of Neurobiology, Harvard Medical School, Boston, MA, 02115, USA
2Department of Biology, University of Namur, 5000 Namur, Belgium

* Equal contributors

Abstract

The proteins CLOCK and BMAL1 form a heterodimeric transcription factor essential to circadian rhythms in mammals. Daily rhythms of CLOCK-BMAL1 DNA binding activity are known to oscillate with target gene expression in vivo. Here we present a highly sensitive assay that recapitulates native CLOCK-BMAL1 DNA binding rhythms from crude tissue extracts, which we call the Clock Protein-DNA Binding Assay (CPDBA). This method can detect less than 2-fold differences in DNA binding activity, and can deliver results in two hours or less using 10 microliters (~10 micrograms) or less of crude extract, while requiring neither specialized equipment nor expensive probes. To demonstrate the sensitivity and versatility of this assay, we show that enzymatic removal of phosphate groups from proteins in tissue extracts or pharmacological inhibition of casein kinase I in cell culture increased CLOCK-BMAL1 DNA binding activity by ~1.5 to ~2 fold, as measured by the CPDBA. In addition, we show that the CPDBA can measure CLOCK-BMAL1 binding to reconstituted chromatin. The CPDBA is a sensitive, fast, efficient and versatile probe of clock function.

Open Peer Review

Referee Status: ✔ ✔ ✔

Invited Referees

<table>
<thead>
<tr>
<th>Version</th>
<th>Published</th>
<th>Report Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>12 Sep 2017</td>
<td>✔ ✔ ✔</td>
</tr>
<tr>
<td>1</td>
<td>03 Aug 2017</td>
<td>✔ ✔ ✔</td>
</tr>
</tbody>
</table>

1 Yoshitaka Fukada, University of Tokyo, Japan
2 Naohiro Kon, Daiichi Sankyo Co., Ltd., Japan
3 Katja A. Lamia, Scripps Research Institute, USA
4 Joanna C. Chiu, University of California, Davis, USA

Discuss this article

Comments (0)
Corresponding author: Alfred Tamayo (Alfred.Tamayo@hms.harvard.edu)

Author roles: Gillessen M: Data Curation, Formal Analysis, Writing – Review & Editing; Kwak PB: Conceptualization, Data Curation, Formal Analysis, Investigation, Validation, Writing – Review & Editing; Tamayo A: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

How to cite this article: Gillessen M, Kwak PB and Tamayo A. A simple method to measure CLOCK-BMAL1 DNA binding activity in tissue and cell extracts [version 2; referees: 3 approved] F1000Research 2017, 6:1316 (doi: 10.12688/f1000research.11685.2)

Copyright: © 2017 Gillessen M et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Grant information: This work was supported by the G. Harold and Leila Y. Mathers Charitable Foundation (CJW) and the U.S. National Institutes of Health Training Grant in Sleep, Circadian, and Respiratory Neurobiology (T32HL07901 to AGT).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Introduction

The maintenance or disruption of circadian rhythms contribute significantly to several areas of health and disease (Asher & Schibler, 2011; Chen & Yang, 2015; Puram et al., 2016; Roenneberg & Merrow, 2016; Sahar & Sassone-Corsi, 2009; Takahashi et al., 2008). Circadian rhythms are daily biological rhythms synchronized by light and dark cycles of the day/night continuum. Underlying circadian rhythms are oscillations of gene expression occurring in nearly all tissues and cells observed to date (Koike et al., 2012; Lamia et al., 2008; Lande-Diner et al., 2015; Zhang et al., 2014). Daily cycles of gene transcription and translation are driven by circadian clocks (Gustafson & Partch, 2015; Mendoza-Viveros et al., 2017; Takahashi, 2017).

An essential component of circadian clocks is the CLOCK-BMAL1 heterodimeric transcription factor (Bunger et al., 2000; Gekakis et al., 1998; Hogenesch et al., 1998; Huang et al., 2012; Lande-Diner et al., 2013; Tamayo et al., 2015). CLOCK-BMAL1 drives the expression of many proteins, including its own repressors, forming the basis of a negative feedback loop (Kume et al., 1999; Sato et al., 2006). The oscillating abundance of transcriptional repressors leads to daily cycles of CLOCK-BMAL1 target gene expression.

Rhythmic CLOCK-BMAL1 binding to target genes is likely critical to the generation of circadian rhythms (Koike et al., 2012; Rey et al., 2011; Ripperger & Schibler, 2006). We have previously demonstrated that immobilized DNA oligonucleotides containing E-box DNA binding motifs (CACGGT) can be used to capture native CLOCK-BMAL1, as measured by mass spectrometry (Tamayo et al., 2015). Here we present a sensitive and versatile method to measure native CLOCK-BMAL1 DNA and chromatin binding from virtually any tissue or cell source in a fast and efficient manner.

Materials and methods

Animals

The mouse strain C57/BL6J (The Jackson Laboratory) was used as wildtype (WT), unless the experiment called for a genetically modified animal, in which case an appropriate control animal was utilized. Bmal1−/− animals were bred from heterozygotes in our facility, therefore WT animals were homozygous Bmal1+/+ littermates (C57/BL6J background). WT controls for Per2-FH animals were mixed C57BL/6J × 129 genetic background (The Jackson Laboratory). Bmal1−/− mice (Bunger et al., 2000) and Per2-FH mice (generated by the Weitz Laboratory of Harvard Medical School) have been previously described (Duong et al., 2011). Mice were entrained to a 12:12 hr light-dark cycle for at least 2 weeks and then were kept in constant darkness for 24 hrs before sacrificing at the indicated circadian time (CT). CT0 corresponds to the time the lights would turn on, CT4 to 4 hours after that point, and so forth. Mice were euthanized under infrared light, and tissues were dissected under room light. Studies were performed in accordance with the protocol approved by the Harvard Medical School Standing Committee on Animals (protocol #03376).

Tissue extracts

Tissue and lysate were kept on ice or at 4°C through all steps. As a first step to each tissue extraction, liver was finely minced using a razor, washed with 40 ml of PBS (phosphate buffered saline) per gram of tissue and centrifuged (400 × g, 5 min) until wash solution was clear (8-10×).

Nuclear extracts were prepared as previously described (Kim et al., 2014), with some amendments. Briefly, tissue was Dounce homogenized with pestle A in Hypotonic Lysis Buffer (250 mM Sucrose, 10 mM HEPES, pH 7.6, protease and phosphatase inhibitors) in a volume 4 times the weight of tissue (e.g. 4 ml/1 g), then centrifuged at 400 × g for 5 min. The pellet was resuspended with 8 ml/1 gr Dounce Buffer (3 ml PBS + 5ml Homogenization Buffer: 2.2 M sucrose, 15 mM KCl, 2 mM EDTA, 10 mM HEPES, pH 7.6), then diluted with 22 ml Homogenization Buffer (assuming 1 gr tissue) and Dounce homogenized with pestle B, followed by ultracentrifugation through a 10 ml sucrose cushion (2.05 M sucrose, 15 mM KCl, 2 mM EDTA, 10 mM HEPES, pH 7.6) at 84,000 × g for 1 hr at 4°C to isolate nuclei (pellet). Nuclei were lysed in nuclear lysis buffer (10 mM Tris-HCl, 300 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.2% TX-100, pH 7.4) containing protease inhibitor cocktail without EDTA (Roche) and phosphatase inhibitor cocktails 2/3 (Sigma-Aldrich). Upon a final centrifugation (20,000 × g, 30 min), the remaining supernatant was liver nuclear extract. For whole tissue extract, the tissue pellet was weighed and resuspended in whole cell extract buffer (10 mM Tris-HCl, 300 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.5% TX-100 [Sigma-Aldrich], pH 7.4, protease and phosphatase inhibitors) in a volume 4× the weight of tissue (e.g. 4 ml/1 g) then Dounce homogenized with pestle A (8 strokes). The homogenate was incubated on ice for 30 min, then centrifuged (20,000 × g, 30 min). The remaining supernatant was whole cell extract. Cytoplasmic extracts were prepared as previously described (Song et al., 2006) and as also appears elsewhere (Aryal et al., 2017), with some amendments. Tissue pellet was weighed and resuspended in Hypotonic Lysis Buffer in a volume 4 times the weight of tissue (e.g. 4 ml/1 g), then Dounce homogenized with pestle A (8 strokes). The resulting homogenate was then subjected to a series of centrifugation steps whereupon only the supernatant was retained. Step 1, 1,000 × g, 10min. Step 2, 2,000 × g, 15 min. Step 3, 8,000 × g, 5 min. Step 4, 20,000 × g, 30 min. The supernatant remaining after the final centrifugation was the cytoplasmic extract.
Cell extracts
To prepare whole cell extracts, PBS washed cells were resuspended in whole cell extract buffer (10 mM Tris-HCl, 300 mM NaCl, 1.5 mM MgCl₂, 1 mM EDTA, 0.5% TX-100, pH 7.4, protease and phosphatase inhibitors) in a volume 4x the weight of tissue (e.g. 4 ml/g), incubated on ice for 30 min, then centrifuged at 20,000 x g for 30 min at 4°C. The remaining supernatant was whole cell extract. 10 µl of whole cell extract diluted in 100 µl final volume of whole cell extract buffer were used for the CPDBA.

Polyacrylamide gel electrophoresis (PAGE) and immunoblotting
SDS-PAGE/immunoblotting was performed using standard methods. NuPAGE 4–12% polyacrylamide gels (Life Technologies) and NuPAGE LDS sample buffer (with β-mercaptoethanol) were used for SDS-PAGE, and proteins were wet-transferred using a Bio-Rad system (20 mM Tris-HCl, 150 mM glycine, 20% methanol, 0.02% SDS) to PVDF membranes (Millipore) for immunoblotting. 5% skim milk (Millipore) in TBS-T (Tris-HCl buffered saline, 0.01% tween-20) was used as a blocking agent, and TBS-T was used in all washing steps. ECL Prime (GE) was used as an HRP chemiluminescent detection substrate, followed by exposure to film (Denville). CN (clear native) PAGE for the detection of mononucleosomes was performed similarly to previously described BN (blue native) PAGE, except Coomassie blue G dye was omitted from all buffers (Kim et al., 2014). The sample and 1 Kb Plus DNA Ladder (NEB) were mixed with loading dye to a final concentration of 0.17 mg/ml Orange G dye (TCI) and 5% glycerol in 10 mM Bis-Tris (pH 7.0). Samples and DNA ladder were separated on Native PAGE 4–16% Bis-Tris gel (Life Technologies) in 1x anode buffer (50 mM Bis-Tris/HCl [pH 7.0]) and 1x cathode buffer (50 mM Tricine [pH 7.0], 15 mM Bis-Tris) at 4°C.

Antibodies
The following antibodies were used:
- anti-CLOCK (Abcam, cat# ab3517),
- anti-BMAL1 (generated by the Weitz Laboratory of Harvard Medical School against TKDDDPHGLTLEAHGQRC and previously described in Tamayo et al., 2015),
- anti-PER2 (ADI, cat# PER21-A),
- anti-CRY1 (Abcam, cat# ab54649),
- anti-HISTONE3 (Abcam, cat# ab1791),
- Amersham ECL Rabbit IgG, HRP-linked F(ab')₂ fragment (from donkey) (GE, cat# NA9340).

All antibodies were polyclonal and raised in rabbits.

DNA-binding oligonucleotide design
Two oligonucleotide designs were used:
1) Binding/quantitation oligonucleotides,
2) Mononucleosome assembly oligonucleotides.

Each design had two forms: E-box DNA, and control DNA. E-box DNA-binding/quantitation oligonucleotides contained three known CLOCK-BMAL1 binding sites from the Per1 locus, consisting of a canonical E-box sequence (CAGCTG) and 10 bp of flanking sequence (Gekakis et al., 1998). E-box DNA-mononucleosome assembly oligonucleotides contained two copies of each E-box binding site (total of 6 E-box sequences) for a total length of 166bp. Mononucleosome formation requires a minimum of 145bp (Luger et al., 1997). Control DNA forms were identical to E-box DNA, except that the E-box sequences were scrambled (GCCTGA). All oligonucleotides contained three restriction enzyme sites (SmaI, XhoI, and HpaI) near the 5’ end for native protein elution. The sense strand of each oligonucleotide pair was labeled with a single biotin moiety at the 5’ end. All oligonucleotide sequences are listed below.

DNA affinity binding
DNA binding of native clock proteins was performed as previously described (Tamayo et al., 2015) with some amendments. Briefly, sense and anti-sense strands of ssDNA binding/quantitation oligonucleotides were combined (1 µM final) and heated to 94°C for 10 min in high salt annealing buffer (10 mM Tris-HCl, 300 mM NaCl, 2.5 mM MgCl₂, 0.05% tween-20), then allowed to cool for 1 hr at 25°C to form dsDNA. 150 µl of dsDNA was incubated with 50 µl Dynabeads M-270 Streptavidin (Life Technologies) for 30 min at room temperature (RT). Unbound DNA was washed away with nuclear lysis buffer or cyto lysis buffer. 50 µl of immobilized DNA was incubated with 150 µl of tissue extract (nuclear or cytoplasmic), and incubated for 1 hr at 4°C. Beads were then washed 3x with nuclear lysis buffer prior to elution by 50 µl LDS sample buffer at 98°C for 5 min.

Clock protein-DNA binding assay (CPDBA)
In PCR tubes (Axygen), 10 µl of Dynabeads M-270 Streptavidin (Life Technologies) were incubated with 100 µl of a concentration range between 1 nM and 100 nM dsDNA binding/quantitation oligonucleotide for 15 min at RT, then washed 3x with high salt annealing buffer. Beads were incubated with ~8 µg protein or 6–10 µl (~1 µg/µl) at a final concentration of ~80 ng/µl (unless a range of extract concentrations is specified) in a final volume of 100 µl nuclear lysis buffer for 30 min at 4°C, then washed 3x with nuclear lysis buffer. Bead-DNA-clock protein conjugates were then incubated with primary antibody (anti-CLOCK or anti-BMAL1) at 1:1000 dilution in TBS-T for 10 min at RT, washed 3x with low salt buffer prior to elution by 3x with TBS-T. Equivalent of 2.5 µl of beads (unless a range is specified) was diluted into 50 µl (final volume) TBS-T in a black/clear bottom 96-well plate (Greiner), 50 µl of ECL Prime chemiluminescent substrate (GE) was added to the well. Data was collected using a Victor3V multi-label reader (Perkin-Elmer) with a 425/60 nm filter. Data analysis and figure preparation were performed using Excel and PowerPoint 2013 (Microsoft).

Immunoprecipitation of PER2-FH
Immunoprecipitation of PER2-FH and associated proteins was performed as previously described (Kim et al., 2014). Briefly, nuclear extracts from livers of Per2-FH mice were incubated with FLAG-M2 agarose beads (Sigma-Aldrich) for 2 hr at 4°C. Beads were washed four times with Buffer C (50 mM Tris-HCl, 250 mM...
NaCl, 1.5 mM MgCl₂, and 0.2% TX-100, pH 7.5). PER2-FH complexes were eluted with 100 µg/ml FLAG peptide (Sigma-Aldrich) in Buffer C for 30 min at 4°C.

Phosphatase treatment of extracts
1.7 µl of 800,000 units/mg λ-phosphatase (NEB) were combined with every 6 µl of nuclear extract and incubated in 100 µl of NEBuffer for PMP (50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Brij 35, pH 7.5) supplemented with 1 mM MnCl₂, for 45 min at 30°C. This reaction was then analyzed with the CPDBA.

Cell culture
Mouse hepatoma cells Hep-1c1c7 (ATCC, CRL-2026) were chosen because they are a mouse cell line derived from liver tissue and have been shown to possess functional circadian clocks (Tong et al., 2010; Yin et al., 2010). Cells were grown in DMEM (Gibco, 1 g/L glucose, L-glutamine, 110 mg/L sodium pyruvate) supplemented with 10% heat inactivated FBS (Atlas), penicillin/streptomycin (Corning) and MEM nonessential amino acids (Cellgro) at 37°C. Cells were passaged using Trypsin/EDTA (Corning).

Pharmacological inhibition of CKI
Hep-1c1c7 cells were allowed to grow for an additional 48 hrs after they reached 90% confluency prior to treatment. Cell density was an important determinant for successful CPDBA. Cells were incubated with 10 µM of PF670462 or equal volume of DMSO (vehicle) for at least 1 hr at RT. The salt concentration of the annealed product was diluted to 150 mM NaCl using low salt annealing buffer (10 mM Tris pH7.4, 300 mM NaCl, 1.5 mM MgCl₂, 0.01% Igepal-CA 630 [Sigma-Aldrich]) and 2x with low salt annealing buffer. Varying concentrations of liver nuclear extracts were incubated with immobilized mononucleosomes for 30 min at RT. Beads were washed 1x with high salt buffer and 2x with wash buffer (10 mM Tris-HCl, 150 mM NaCl, 1.5 mM MgCl₂, 0.1% TX-100). Beads were analyzed by the CPDBA as described above, or proteins were eluted with LDS sample buffer as described above for SDS-PAGE/immunoblotting.

Oligonucleotides
E-box DNA-binding/quantitation oligonucleotide sense: Biotin5’AGTAGTGTTAACCCGGGCTCGAGCACTATTAGC CACGTGACAGTGTAAGCTACGAGCGGCCCTCAAGTCC TGAGCCAGGGA3’

E-box DNA-binding/quantitation oligonucleotide anti-sense: 5’TCCCTGACAGTGTAAGGTGCCACGTGGCTCAGGACT TACACTGTCAGCGCTCAAGTCC TGAGCCAGGGA3’

Control DNA-binding/quantitation oligonucleotide sense: Biotin5’AGTAGTGTTAACCCGGGCTCGAGCACTATTAGC CACGTGACAGTGTAAGCTACGAGCGGCCCTCAAGTCC TGAGCCAGGGA3’

Control DNA-binding/quantitation oligonucleotide anti-sense: 5’TCCCTGACAGTGTAAGGTGCCACGTGGCTCAGGACT TACACTGTCAGCGCTCAAGTCC TGAGCCAGGGA3’

E-box DNA-mononucleosome assembly sense: Biotin5’AGTAGTGTTAACCCGGGCTCGAGCACTATTAGC CACGTGACAGTGTAAGCTACGAGCGGCCCTCAAGTCC TGAGCCAGGGA3’

E-box DNA-mononucleosome assembly anti-sense: 5’TCCCTGACAGTGTAAGGTGCCACGTGGCTCAGGACT TACACTGTCAGCGCTCAAGTCC TGAGCCAGGGA3’

Control DNA-mononucleosome assembly sense: Biotin5’AGTAGTGTTAACCCGGGCTCGAGCACTATTAGC CACGTGACAGTGTAAGCTACGAGCGGCCCTCAAGTCC TGAGCCAGGGA3’

Control DNA-mononucleosome assembly anti-sense: 5’TCCCTGACAGTGTAAGGTGCCACGTGGCTCAGGACT TACACTGTCAGCGCTCAAGTCC TGAGCCAGGGA3’

Results
Relative quantitation and specificity of CLOCK-BMAL1 DNA binding by the CPDBA
We have developed a method to quantitate native CLOCK-BMAL1 DNA binding on immobilized E-box DNA, termed the clock protein-DNA binding assay, or CPDBA (Figure 1A). 10 µl of nuclear extract from wildtype mouse liver (WT extract) was
Figure 1. Relative quantitation and specificity of CLOCK-BMAL1 DNA binding by CPDBA. (A) CPDBA design. E-box DNA (or E-box scrambled Control DNA) is immobilized onto a bead substrate. Immobilized DNA is incubated with cell or tissue extract, washed, incubated with primary antibody against CLOCK or BMAL1, washed, incubated with secondary antibody (HRP linked), then washed a final time. The immobilized antibody-protein-DNA complex is then incubated with chemiluminescent substrate (ECL), and analyzed by spectrophotometry (luminescence at 425/60 nm). Counts are arbitrary units. (B) CPDBA was applied to WT nuclear extracts or Bmal1−/− nuclear extracts (KO). The x-axis represents the amount of immobilized antibody-protein-DNA complex (in µl of magnetic beads), used in the final step of the CPDBA, and in the case of WT extract incubated with E-box DNA, corresponds to CLOCK-BMAL1-DNA probed with anti-BMAL1. This experiment was repeated (n=3) with a single volume of immobilized antibody-protein-DNA complex using anti-CLOCK (C) or anti-BMAL1 (D). BMAL1 binding to immobilized DNA was measured from a series of WT nuclear extract dilutions (1 = 16 µg of extract or 160 ng/µl final extract concentration with magnetic beads) while keeping the DNA concentration constant (E), or a series of DNA concentrations were used while keeping the extract concentration constant (F).
incubated with immobilized E-box DNA or scrambled E-box DNA (Control DNA) at a single concentration. As an additional control for specificity, we performed parallel experiments using nuclear extracts harvested from Bmal1−/− knockout animals (BKO Extract). Upon extract incubation and anti-BMAL1/secondary antibody incubation with immobilized DNA, varying amounts of immobilized-DNA-protein-antibody (or CLOCK-BMAL1-DNA in the case of WT extract incubated with E-box DNA) were incubated with HRP chemiluminescent substrate, and luminescence data was collected. The presence of BMAL1, as detected by HRP chemiluminescence, was shown to be virtually linear within a given range of CLOCK-BMAL1-DNA, and significantly greater than all control signals (Figure 1B/CPDBA data). This experiment was repeated with a single concentration of CLOCK-BMAL1-DNA using anti-CLOCK (Figure 1C/CPDBA data) and anti-BMAL1 for detection (Figure 1D/CPDBA data), demonstrating a ~5 fold and ~10 fold signal increase over control conditions, respectively. The control conditions were nearly identical to each other, indicating that little or no CLOCK binds to E-box DNA in the absence of BMAL1 in vitro. In addition, BMAL1 quantitation showed a dose-dependent relationship with both tissue extract (Figure 1E/CPDBA data) and DNA concentration (Figure 1F/CPDBA data).

As a quality control, we performed similar DNA binding experiments using SDS-PAGE/Immunoblotting to qualitatively assess clock protein binding to E-box DNA (see Supplementary Material). We observed that very little CLOCK and BMAL1 were bound to PER2 from cytoplasmic extracts (C) as compared to nuclear extracts (N), as shown by Anti-FLAG co-immunoprecipitation experiments from extracts containing PER2-FLAG-HA (Figure S1A/Uncropped Figure S1A-B). Since PER2 and CRY1 are known to bind E-box DNA through their interactions with CLOCK-BMAL1, this observation allowed us to use cytoplasmic extracts as an additional negative control for clock protein DNA binding in vitro. Nuclear or cytoplasmic extracts were incubated with immobilized E-box DNA or Control DNA (scrambled E-box), and bound proteins were analyzed by SDS-PAGE/immunoblotting for PER2, CRY1, CLOCK and BMAL1. Nuclear but not cytoplasmic PER2, CRY1, CLOCK and BMAL1 bound to E-box DNA (Figure S1B/Uncropped Figure S1C), further demonstrating specific clock protein interactions with E-box DNA in vitro. Nuclear and cytoplasmic markers were distributed as expected (Figure S2/Uncropped Figure S2). While these results do not preclude the existence of BMAL1 in the cytoplasm, as previously reported by Kwon et al., 2006; Lipton et al., 2015, they suggest that BMAL1 is a predominately nuclear protein.

Taken together, these experiments demonstrate that native CLOCK-BMAL1 DNA binding can be relatively quantitated using tissue extracts as a source of protein and naked DNA as a binding substrate.

**Rhythmic CLOCK-BMAL1 DNA binding measured by CPDBA**

Several studies have demonstrated the circadian rhythmicity of CLOCK-BMAL1 E-box DNA binding *in vivo*, as observed by chromatin immunoprecipitation (ChIP) (Duong et al., 2011; Koike et al., 2012; Ripperger & Schibler, 2006). We asked if CLOCK-BMAL1 DNA binding activity would also oscillate when measured by the CPDBA.

Nuclear extracts were prepared from livers harvested from wildtype mice every 4 hours across circadian time or CT (see methods), and analyzed by SDS-PAGE/immunoblotting for CLOCK, BMAL1, PER2 and CRY1 (Figure 2A/Uncropped Figure 2). CLOCK and BMAL1 levels were mostly stable across the day, while PER2 and CRY1 levels were highly rhythmic. We then applied the
CPDBA to these extracts to monitor CLOCK (Figure 2B/CPDBA data) and BMAL1 (Figure 2C/CPDBA data) DNA binding. In both cases, DNA binding reached its peak at CT4 and its trough 12 hours later at CT16, revealing very similar binding patterns to those demonstrated by in vivo ChIP experiments. These results show that rhythmic CLOCK-BMAL1 DNA binding activity can be recapitulated using the CPDBA, validating its use as a probe of CLOCK-BMAL1 function.

CPDBA captures CLOCK-BMAL1 modulation in tissue extracts and cells

Phosphorylation is the most extensively studied post-translational modification involved in circadian clocks (Dardente et al., 2007; Kondratov et al., 2006; Lee et al., 2014; Reischl & Kramer, 2011), and has been implicated in the regulation of CLOCK-BMAL1 DNA binding (Yoshitane et al., 2009; Wang et al., 2013).

Nuclear extracts prepared from mouse liver were treated with λ-phosphatase or mock conditions, and analyzed by SDS-PAGE/immunoblotting for CLOCK and BMAL1 (Figure 3A/Uncropped Figure 3A), indicating similar levels in both conditions. CPDBA was then applied to these extracts to quantitate CLOCK (Figure 3B/CPDBA data) and BMAL1 (Figure 3C/CPDBA data) DNA binding to E-box DNA or scrambled E-box DNA (Control DNA). Data across experiments were normalized to the mock treated/E-box DNA bound sample. DNA binding activity increased between 1.5- to 2-fold upon treatment of tissue extract with phosphatase using either antibody.

Pharmacological inhibition of CKIε/δ has previously been shown to severely disrupt circadian rhythms (Isojima et al., 2009; Meng et al., 2010). In this study, mouse hepatoma cells in culture were incubated with a specific kinase inhibitor of CKIε/δ (PF670462, Figure 3D). Extracts were made from Hep-1c1c7 cells incubated with vehicle (DMSO) or 10 µM CKIε/δ inhibitor PF670462. Extracts were analyzed by SDS-PAGE/immunoblotting for CLOCK and BMAL1, and coomassie stained for loading controls. (E, F) CPDBA was applied to these extracts to measure binding of CLOCK and BMAL1 to E-box DNA. All data were normalized to the E-box DNA/vehicle treated condition (normalized to 1). (*P<0.0001, two-tailed, unequal variance).

Figure 3. CPDBA captures CLOCK-BMAL1 modulation in tissue extracts and cells. (A) Liver nuclear extracts were treated with lambda phosphatase (APPase) or mock buffer (Mock). Extracts were analyzed by SDS-PAGE/immunoblotting for the presence of CLOCK and BMAL1, and coomassie stained for loading controls. (B, C) CPDBA was applied to these extracts to measure binding of CLOCK (B) or BMAL1 (C) to E-box DNA. All data were normalized to the E-box DNA/mock treated condition (normalized to 1). (* P<0.0001, two-tailed, unequal variance). (D) Extracts were made from Hep-1c1c7 cells incubated with vehicle (DMSO) or 10 µM CKIε/δ inhibitor PF670462. Extracts were analyzed by SDS-PAGE/immunoblotting for CLOCK and BMAL1, and coomassie stained for loading controls. (E, F) CPDBA was applied to these extracts to measure binding of (E) CLOCK and (F) BMAL1 to E-box DNA. All data were normalized to the E-box DNA/vehicle treated condition (normalized to 1). (*P<0.0001, two-tailed, unequal variance).
IC50 for CKIε and CKIδ are 7.7 nM and 14 nM, respectively) or DMSO (vehicle) for 48 hours. This treatment did not discernably affect cell viability. Whole cell extracts were analyzed by SDS-PAGE/immunoblotting for CLOCK and BMAL1 indicating similar or lower levels (as shown) of CLOCK and BMAL1 in the PF670462 treated condition (Figure 3D/Uncropped Figure 3B). CPDBA was applied to these extracts to quantitate CLOCK (Figure 3E/CPDBA data) or BMAL1 (Figure 3F/CPDBA data), and the data across experiments were normalized to the vehicle treated/E-box DNA incubated set. Pharmacological inhibition of CKIε/δ resulted in a ~1.5-fold increase of CLOCK-BMAL1 DNA binding activity. Taken together, these results demonstrate the sensitivity and versatility of the CPDBA by capturing less than 2-fold differences in CLOCK-BMAL1 DNA binding activity in a tissue extract and cell culture model of clock modulation.

Modified CPDBA used to quantify CLOCK-BMAL1 binding to mononucleosomes

 Previous studies have indicated that chromatin modifications alter clock protein access to gene regulatory sites (Brown et al., 2005; Doi et al., 2006; Duong et al., 2011; Duong & Weitz, 2014; Etchegaray et al., 2003; Kim et al., 2014; Koike et al., 2012; Ripperger & Schibler, 2006; Tamayo et al., 2015). Here we asked if native CLOCK-BMAL1 binding to reconstituted nucleosomes can be measured using the CPDBA.

Mononucleosomes were reconstituted using histone octamers, chromatin assembly chaperones and a biotin tagged 166 base pair oligonucleotide containing E-box sequences (Control DNA), then analyzed by CN PAGE/fluorescence DNA labeling (Figure 4A). Reaction mixtures containing histone octamers shifted the oligonucleotide’s apparent molecular weight to ~600bp, indicating the formation of mononucleosomes (Figure 4A) (White et al., 2016). Mononucleosomes containing E-box sequences or scrambled E-box sequences (Control DNA) were immobilized using streptavidin coated magnetic beads, then incubated with nuclear extracts prepared from mouse liver tissue. Bound proteins were analyzed by SDS-PAGE/immunoblotting for CLOCK, BMAL1 and HISTONE3 (Figure 4B/Uncropped Figure 4), demonstrating that CLOCK-BMAL1 bound specifically to E-box sequences within mononucleosomes in vitro. We applied the CPDBA to varying concentrations of nuclear extract using anti-CLOCK (Figure 4C/CPDBA data), demonstrating a relationship between extract concentration and E-box specific CLOCK binding to mononucleosomes.

Dataset 1. Uncropped images of SDS-PAGE/Immunoblots used to construct Figures 2A, 3A, 3D, 4B, S1A, S1B and S2
http://dx.doi.org/10.5256/f1000research.11685.d169055

Dataset 2. Clock Protein-DNA Binding Assay (CPDBA) data
http://dx.doi.org/10.5256/f1000research.11685.d169056

Raw data generated by the CPDBA used to construct Figures 1B–F, 2B, 2C, 3B, 3C, 3E, 3F and 4C

Figure 4. Modified CPDBA used to Quantitate CLOCK-BMAL1 Binding to Mononucleosomes. (A) Free dsDNA containing E-box DNA or scrambled E-box DNA (Control DNA) was incubated with or without core histones, and reconstituted mononucleosomes were analyzed using CN-PAGE stained with SYBR gold. (B) Immobilized mononucleosomes were incubated with liver nuclear extracts. CLOCK-BMAL1 binding to mononucleosomes was assessed using SDS-PAGE/immunoblotting for CLOCK, BMAL1, and HISTONE3. (C) Immobilized mononucleosomes were used in place of naked DNA in CPDBA to measure CLOCK binding to E-box DNA within mononucleosomes using a series of nuclear extract concentrations (n=3).
Discussion
Previously, we coupled DNA binding selection to quantitative mass spectrometry and discovered novel CLOCK-BMAL1 interacting proteins and chromatin modifying activities (Tamayo et al., 2015). Here, we present a simple method to measure native CLOCK-BMAL1 DNA and chromatin binding activity from tissue or cell extracts that we term the clock protein-DNA binding assay (CPDBA). Using the CPDBA, we reproduced rhythmic CLOCK-BMAL1 binding from crude tissue extracts in a manner strikingly similar to previously reported chromatin immunoprecipitation (ChIP) patterns (Duong et al., 2011; Etchebarry et al., 2003; Kim et al., 2014; Koike et al., 2012; Rey et al., 2011; Ripperger & Schibler, 2006; Tamayo et al., 2015). In addition, we show that the CPDBA can be adapted to quantify CLOCK-BMAL1 binding to reconstituted chromatin, in the form of mononucleosomes. This variation of the CPDBA could be used to provide in vivo ChIP studies with mechanistic insights. These results indicate that the CPDBA is a viable tool for measuring native CLOCK-BMAL1 DNA binding activity. As such, the CPDBA could complement a variety of research approaches that require monitoring of circadian clock function.

To demonstrate the versatility of the CPDBA, we used it to measure CLOCK-BMAL1 DNA binding activity in both tissue and cell culture extracts, while also using two different approaches to modulate CLOCK-BMAL1 activity. Phosphatase treatment of tissue extracts increased CLOCK-BMAL1 DNA binding as measured by the CPDBA, while treating cells with a specific inhibitor of Casein Kinase ε/δ (CKε/δ) yielded similar results. In both cases, the differences between control and experimental conditions were 2-fold or less, demonstrating the sensitivity of the CPDBA. We also performed related experiments using an electrophoretic mobility shift assays (EMSA) to monitor the effect of phosphatase on purified nuclear PER complex (containing CLOCK-BMAL1), and we again detected an increase in DNA binding upon phosphatase treatment (Aryal et al., 2017). EMSA may surpass the CPDBA in sensitivity and detection limit, since it can use radiolabeled DNA probes to quantify protein-DNA binding. However, the CPDBA is less technically cumbersome and more scalable than EMSAs. We have successfully performed the CPDBA with as little as 6 µl of nuclear extract (~6 µg protein) in 2 hours. While this is already fast and efficient, the CPDBA can likely be improved by further optimization.

The CPDBA is similar to previously reported assays developed for different DNA binding proteins (Brand et al., 2010; Fischer et al., 2016). While not modeled upon previously described assays, the CPDBA shares features that make it amenable to high throughput approaches, with the potential for automation (Brand et al., 2013). Furthermore, this method can theoretically be applied to tissue or cells of virtually any source; an important feature given that functional clocks have been observed in most tissues. In conclusion, we submit the CPDBA as a sensitive, fast, efficient and versatile probe of clock function.

Data availability
Dataset 1: Uncropped images of SDS-PAGE/Immunoblots used to construct Figures 2A, 3A, 3D, 3E, S1A, S1B and S2. doi: 10.5256/f1000research.11685.d169055 (Gillessen et al., 2017a)

Dataset 2: CPDBA data. Raw data generated by the CPDBA used to construct Figures 1B–F, 2B, 2C, 3B, 3C, 3E, 3F and 4C. doi: 10.5256/f1000research.11685.d169056 (Gillessen et al., 2017b)

Author contributions
A.G.T. conceived of the study and designed experiments. M.G., P.B.K. and A.G.T. carried out the research. M.G. contributed as part of a student internship (University of Namur, Belgium) at Harvard Medical School. A.G.T. prepared the manuscript. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests
No competing interests were disclosed.

Grant information
This work was supported by the G. Harold and Leila Y. Mathers Charitable Foundation (CJW) and the U.S. National Institutes of Health Training Grant in Sleep, Circadian, and Respiratory Neurobiology (T32HL07901 to AGT).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments
We thank Charles J. Weitz in the Department of Neurobiology of Harvard Medical School for allowing to us to perform this work in his laboratory. We thank Michael Gebert (currently at Baxter International) for contributing to extract preparations. We thank Ming Liu (Harvard Medical School) for managing mouse colonies. We also thank Charles J. Weitz, Hao A. Duong and Rajindra P. Aryal for critical readings of this manuscript during preparation (Harvard Medical School).
**Supplementary material**

**Figure S1.** Native clock proteins bind specifically to immobilized E-box DNA sequences. Cytoplasmic (C) and nuclear (N) extracts were prepared from the livers of mice expressing PER2-FLAG-HA at CT16. (A) SDS-PAGE/immunoblotting was used to assess the presence of PER2, CLOCK, CRY1 and BMAL1 (equal loading by volume). Anti-FLAG (Sigma-Aldrich) or IgG negative control was used to co-immunoprecipitate clock proteins from C or N extracts. (B) Immobilized dsDNA containing E-box sequences (E-box DNA) or scrambled E-box sequences (Control DNA) were incubated with either C or N extracts. Bound proteins were eluted under denaturing conditions, then analyzed by SDS-PAGE/immuno-blotted for clock proteins.

Click here to access the data.

**Figure S2.** Segregation of nuclear and cytoplasmic markers from mouse liver extracts. Nuclear and cytoplasmic extracts were prepared from mouse livers harvested over circadian time. Extracts were analyzed by SDS-PAGE/immuno-blotted for the presence of RNA polymerase II (nuclear marker) and tubulin (cytoplasmic marker).

Click here to access the data.

**References**


Chen L, Yang G: Recent advances in circadian rhythms in cardiovascular system. Front Pharmacol. 2015; 6: 71. Published Abstract | Publisher Full Text | Free Full Text


Lande-Diner L, Stewart-Ornstein J, Weitz CJ, et al.: Single-cell analysis of


Open Peer Review

Current Referee Status: ✔ ✔ ✔

Version 2

Referee Report 19 September 2017
doi:10.5256/f1000research.13702.r25946

Katja A. Lamia
Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA, USA

I thank the authors for their corrections and clarifications and approve the revised manuscript which describes a useful novel method for measuring circadian transcription factors' DNA binding activities.

Competing Interests: No competing interests were disclosed.

Referee Expertise: Circadian biology

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 14 September 2017
doi:10.5256/f1000research.13702.r25947

Joanna C. Chiu
Department of Entomology and Nematology, College of Agricultural and Environmental Sciences, University of California, Davis, Davis, CA, USA

I am satisfied with the authors' revisions.

Competing Interests: No competing interests were disclosed.

Referee Expertise: Molecular chronobiology

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 13 September 2017
doi:10.5256/f1000research.13702.r25945

✔
Yoshitaka Fukada¹, Naohiro Kon²  
¹ Department of Biological Sciences, School of Science, University of Tokyo, Tokyo, Japan  
² Medical Science Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan

We would agree to the revision by the authors.

**Competing Interests:** No competing interests were disclosed.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Joanna C. Chiu**  
Department of Entomology and Nematology, College of Agricultural and Environmental Sciences, University of California, Davis, Davis, CA, USA

Gillessen *et al.* presents a simple assay to measure DNA binding activity of CLOCK-BMAL1 heterodimers, the major transcriptional activators of clock-regulated genes in animals. They show that the Clock Protein-DNA Binding Assay (CPDBA) can recapitulate CLOCK-BMAL1 DNA binding rhythms from tissue nuclear extracts, detect less than 2-fold differences, and can be used as an alternative to approaches including ChIP-qPCR and gel-shift (EMSA). As opposed to ChIP-qPCR and EMSA, CPDBA may be more amenable to automation and/or high throughput screening of mutations or chemicals to modulate CLOCK-BMAL1 DNA binding activity. I applaud them for going one step further by confirming the functionality of their assay in the context of reconstituted chromatin (mononucleosomes). Overall, this is an excellent and efficient tool, and should not be too difficult for chronobiology colleagues to adopt, especially compared to ChIP and EMSA. I, for one, am excited to try it out.

Specific comments that the authors should address are detailed below. Most of them are minor.

1. The authors emphasize on a number of occasions that crude tissue extracts can serve as input for the CPDBA (e.g. in the Abstract). In most of the experiments, nuclear extracts as opposed to whole cell extracts were used. Obviously CLOCK-BMAL1 DNA binding takes place in the nucleus, and tissue nuclear extracts will likely produce the cleanest results. Have the authors compare the results of CPDBA using whole cell extracts vs. nuclear extracts? Is it necessary to perform fractionation to collect nuclear extracts for CPDBA. If yes, perhaps the authors should include this recommendation.

2. In the Abstract, the authors mention the assay uses less than 10 microliters or less of crude extract. Perhaps they should specify the protein amount instead of volume. They do state in the Discussion that they assume 1 microliter equals roughly 1 microgram (for their extract), but maybe they need to clarify that in the Abstract.
3. The CLOCK-centered Introduction is clear, concise, and well-written, highlighting the importance of studying CLOCK-BMAL1 interaction to DNA in the context of mammalian clock. The authors should consider adding a paragraph discussing factors/modifications that are known to affect DNA binding activity of CLOCK-BMAL1.

4. CPDBA uses HRP conjugated secondary antibodies and chemiluminescent detection. Have the authors consider the use of fluorescent-labeled antibodies and multiplexing? Would fluorescent-labeled antibodies be more quantitative than chemiluminescent detection, and present less problems with signal saturation?

5. The mobility shift the authors intend to show in Figure 3A (and 3D) in cell extracts that are untreated and treated with lambda phosphatase is not obvious at all. Are the authors expecting a significant shift in mobility shift? The authors could try using phostag gel to accentuate the shift.

6. In the section for “Oligonucleotides”, the authors need to add “Biotin” to the first and third primers, just as they did for the mononucleosome assembly primers.

7. Can the authors explain the discrepancies in Y-axis values (DNA binding activity) for Figure 2B vs 2C? The difference in CLOCK (Fig. 2B) and BMAL (Fig. 2C) binding can perhaps be explained by the use of different antibodies. But what about the difference between Figure 2C and Figure 1? The values for Figure 2C seems oddly low, given that both figures are using liver nuclear extracts.

8. Since I am interested in the regulation of clock protein function by post-translational modifications such as phosphorylation, I would be interested to see the authors discuss the possibility of using phosphospecific antibodies (instead of the polyclonal antibodies they list) to detect if specific isoforms of CLOCK and BMAL1 bind preferentially to DNA.

**Is the rationale for developing the new method (or application) clearly explained?**  
Yes

**Is the description of the method technically sound?**  
Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**  
Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**  
Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**  
Yes

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Molecular chronobiology
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 08 Sep 2017

Alfred Tamayo, Harvard Medical School, USA

Dear Dr. Chiu. A new version of this manuscript has been submitted with the changes indicated below. Also find below answers to your questions and comments.

1.) “The authors emphasize on a number of occasions that crude tissue extracts can serve as input for the CPDBA (e.g. in the Abstract). In most of the experiments, nuclear extracts as opposed to whole cell extracts were used. Obviously CLOCK-BMAL1 DNA binding takes place in the nucleus, and tissue nuclear extracts will likely produce the cleanest results. Have the authors compare the results of CPDBA using whole cell extracts vs. nuclear extracts? Is it necessary to perform fractionation to collect nuclear extracts for CPDBA. If yes, perhaps the authors should include this recommendation.”

Answer: It is not necessary to use nuclear extracts in the CPDBA, whole cell extracts also work. However we have not performed head-to-head comparisons of nuclear extracts versus whole cell extracts, so we cannot recommend one over the other.

2.) “In the Abstract, the authors mention the assay uses less than 10 microliters or less of crude extract. Perhaps they should specify the protein amount instead of volume. They do state in the Discussion that they assume 1 microliter equals roughly 1 microgram (for their extract), but maybe they need to clarify that in the Abstract.”

Answer: A better description of the protein concentrations of extracts used in all assays, unless a concentration range is stated, has been added to Materials and Methods: “Beads were incubated with ~8 µg protein or 6–10 µl (~1 µg/µl) at a final concentration of ~80 ng/µl of extract (unless a range of extract concentrations is specified)...” In addition, the concentration equivalent to 1 in Figure 1E is now noted in the legend: “1 = 16 µg of extract or 160 ng/µl final extract concentration with magnetic beads.”

3.) “The CLOCK-centered Introduction is clear, concise, and well-written, highlighting the importance of studying CLOCK-BMAL1 interaction to DNA in the context of mammalian clock. The authors should consider adding a paragraph discussing factors/modifications that are known to affect DNA binding activity of CLOCK-BMAL1.”

Answer: A more detailed discussion of factors affecting DNA binding may not be in keeping with the spirit of a methods article. However, such a discussion is certainly worth having in light of our findings, so we included it in this comment (below), which is also publically available.

The molecular underpinnings governing CLOCK-BMAL1 DNA binding activity are not fully elucidated. Repressor proteins physically interact with CLOCK-BMAL1, suggesting steric or post-translational regulation of CLOCK-BMAL1 activity (Ye et al. 2011, Ye et al. 2014, Chiou et al. 2016, Michael et al. 2017). In addition, a body of work indicates epigenetic regulation of DNA accessibility as an underlying cause (Etchegary et al. 2003, Brown et al. 2005, Doi et al. 2006, Ripperger and Schibler 2006, Duong et al. 2011, Koike et al. 2012). Direct repression of CLOCK-BMAL1 activity and gating of chromatin accessibility are not mutually exclusive, therefore,
how are these modalities integrated?

Phosphorylation dependent restriction of CLOCK-BMAL1 DNA binding has been implicated by previous reports. Mutagenic replacement of serine residues with phospho-mimicking amino acids within the basic helix-loop-helix (bHLH) domains of either CLOCK (S38, S42) or BMAL1 (S78) disrupts DNA binding (Yoshitane et al. 2009, Wang et al. 2013). However, CLOCK phosphorylation at S440, S441, and S446 is correlated with CLOCK-BMAL1 activation (Robles et al. 2016). These findings point to an intricate coordination of clock protein phosphorylation tied to structure-function relationships, which we may begin to unravel using methods described in this study.

4.) “CPDBA uses HRP conjugated secondary antibodies and chemiluminescent detection. Have the authors consider the use of fluorescent-labeled antibodies and multiplexing? Would fluorescent-labeled antibodies be more quantitative than chemiluminescent detection, and present less problems with signal saturation?”

Answer: Yes we have considered using fluorescent-labeled antibodies as well as other alterations to the original technique such as TR-FRET (time resolved fluorescence energy transfer) and ALPHAScreen technology, however, we haven't tried these adaptations as yet.

5.) “The mobility shift the authors intend to show in Figure 3A (and 3D) in cell extracts that are untreated and treated with lambda phosphatase is not obvious at all. Are the authors expecting a significant shift in mobility shift? The authors could try using phostag gel to accentuate the shift.”

Answer: In general, upon phosphatase treatment of extract, we did not see a mobility shift for CLOCK, we did see a subtle shift for BMAL1 and a significant shift for PER2 (not shown) using standard SDS-PAGE/immunoblotting. As you point out, a lack of shift does not exclude effective dephosphorylation. Using phostag gels is an excellent suggestion, though we have not attempted. MS analysis of immunoprecipitated proteins from phosphatase treated extracts would also be informative, if less practical. However, a more thorough analysis of the role of phosphorylation in CLOCK-BM料1 DNA binding is beyond the scope of this manuscript.

6.) “In the section for “Oligonucleotides”, the authors need to add “Biotin” to the first and third primers, just as they did for the mononucleosome assembly primers.”

Answer: The requested modification has been made to Materials and Methods.

7.) “Can the authors explain the discrepancies in Y-axis values (DNA binding activity) for Figure 2B vs 2C? The difference in CLOCK (Fig. 2B) and BMAL (Fig. 2C) binding can perhaps be explained by the use of different antibodies. But what about the difference between Figure 2C and Figure 1? The values for Figure 2C seems oddly low, given that both figures are using liver nuclear extracts prepared.”

Answer: Figure 2B represents raw counts from a single set of nuclear extracts prepared simultaneously, i.e. one set of mice. While Figure 2C represents independently prepared extracts from several sets of mice. Raw counts across sets of mouse extracts were too variable to be represented in the same graph. Independently prepared extracts were used in Figure 2C and Figure 1, which is why the scales are different. We do not fully understand the reason behind this, but it is an important technical observation.
8.) “Since I am interested in the regulation of clock protein function by post-translational modifications such as phosphorylation, I would be interested to see the authors discuss the possibility of using phosphospecific antibodies (instead of the polyclonal antibodies they list) to detect if specific isoforms of CLOCK and BMAL1 bind preferentially to DNA.”

Answer: This is a very interesting suggestion, as using phospho-specific antibodies in the CPDBA could give an initial indication of differential DNA binding affinities across phosphospecies either across circadian time and/or within a population of molecules at a given CT. Perhaps it would be best if the assay could be multiplexed to use phosho-state and non-phospho specific antibodies simultaneously from the same sample.

Best Regards

**Competing Interests:** No competing interests were disclosed.

---

Referee Report 21 August 2017

doi:10.5256/f1000research.12624.r24783

**Katja A. Lamia**
Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA, USA

Gillessen, Kwak, and Tamayo describe a method for measuring the interaction of CLOCK and BMAL1 purified from cellular or tissue extracts with either naked DNA or nucleosomes including an established CLOCK-BMAL1 binding sequence containing several E-boxes. The manuscript is well written, and the method will be broadly useful, especially as it could be adapted to other transcription factors by altering the target DNA sequences. Given that it is a method description, it is important that all details of the protocol are clear and I include here some suggestions for clarification.

Materials and methods:

1. In the description of the preparation of tissue extracts, the following is insufficiently clear: “…tissue was Dounce homogenized with pestle A, centrifuged, then Dounce homogenized with pestle B, followed by…” Was the supernatant discarded after centrifugation between homogenization with pestle A and pestle B? If so, was the pellet resuspended again in the same buffer?

2. Please provide detailed composition and volumes of buffers used for initial homogenization and sucrose cushion centrifugation.

3. In the list of antibodies for the last item, either delete “ECL” or include the full product name “Amersham ECL Rabbit IgG, HRP-linked F(ab’)2 fragment (from donkey)”. Also, I can’t find a product number with a “V” at the end – is that a typo?

4. Either place the oligonucleotide sequences within the section describing “DNA-binding oligonucleotide design” or include a sentence stating that the sequences are listed below.

5. Nowhere in the manuscript does it state the concentration of extracts that is used in the assays and this is critical information. Perhaps this was meant to be included in the section describing the CPDBA where it states “Beads were incubated with 6-10 l of extract (unless a range of
concentrations is specified)…”

6. The section titled “Pharmacological inhibition of CKIe/d” also includes details of preparation of cell extracts, which might fit more logically as a separate section following preparation of tissue extracts.

Results:
1. Related to point #5 above, there is no mention of the concentration of extract used in experiments shown in Fig. 1. What does arbitrary units refer to on the x and y axes in Fig. 1B? In Fig. 1E and Fig. 4C, the x axis is labeled “fold dilution” or “l extract” but it would be much more informative to know what concentration of extract is included in the assay.

2. In Figs 3A and 3D, the legend refers to Western blot detection of PER2 and CKId that does not appear in the figure.

3. The text states that there are similar levels of CLOCK and BMAL1 protein in each condition in Fig 3D but the figure shows much less CLOCK and BMAL1 protein in the extract treated with PF671462. Both Fig. 3A and 3D should include a loading control blot as well. Since the change in protein amounts appears to be opposite to the change in binding measured, this does not invalidate the conclusions but the data should be described accurately in the text.

Is the rationale for developing the new method (or application) clearly explained?
Yes

Is the description of the method technically sound?
Yes

Are sufficient details provided to allow replication of the method development and its use by others?
Partly

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?
Partly

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Sep 2017
Alfred Tamayo, Harvard Medical School, USA
Dear Dr. Lamia. A new version of this manuscript has been submitted with the changes indicated below.

1.) “In the description of the preparation of tissue extracts, the following is insufficiently clear: “…tissue was Dounce homogenized with pestle A, centrifuged, then Dounce homogenized with pestle B, followed by…” Was the supernatant discarded after centrifugation between homogenization with pestle A and pestle B? If so, was the pellet resuspended again in the same buffer?”

Answer: Please see changes made to Materials and Methods: “The pellet was resuspended within 8 ml/1 gr Dounce Buffer (3 ml PBS + 5ml Homogenization Buffer: 2.2 M sucrose, 15 mM KCl, 2 mM EDTA, 10 mM HEPES, pH 7.6), then diluted with 22 ml Homogenization Buffer (assuming 1 gr tissue)”

2.) “Please provide detailed composition and volumes of buffers used for initial homogenization and sucrose cushion centrifugation.”

Answer: Requested information added to Materials and Methods: “…Hypotonic Lysis Buffer (250 mM Sucrose, 10 mM HEPES, pH 7.6, protease and phosphatase inhibitors) in a volume 4 times the weight of tissue (e.g. 4 ml/1 g), then centrifuged at 400 × g for 5 min. The pellet was resuspended with 8 ml/1 gr Dounce Buffer (3 ml PBS + 5ml Homogenization Buffer: 2.2 M sucrose, 15 mM KCl, 2 mM EDTA, 10 mM HEPES, pH 7.6), then diluted with 22 ml Homogenization Buffer (assuming 1 gr tissue) and Dounce homogenized with pestle B, followed by ultracentrifugation through a 10 ml sucrose cushion (2.05 M sucrose, 15 mM KCl, 2 mM EDTA, 10 mM HEPES, pH 7.6) at 84,000 × g for 1 hr at 4°C to isolate nuclei (pellet)”

3.) “In the list of antibodies for the last item, either delete “ECL” or include the full product name “Amersham ECL Rabbit IgG, HRP-linked F(ab’)2 fragment (from donkey)”. Also, I can’t find a product number with a “V” at the end – is that a typo?”

Answer: Yes, the typo has been corrected and the requested information modified and added.

4.) “Either place the oligonucleotide sequences within the section describing “DNA-binding oligonucleotide design” or include a sentence stating that the sequences are listed below.”

Answer: Requested sentence has been added.

5.) “Nowhere in the manuscript does it state the concentration of extracts that is used in the assays and this is critical information. Perhaps this was meant to be included in the section describing the CPDBA where it states “Beads were incubated with 6-10 l of extract (unless a range of concentrations is specified)”?”

Answer: Changes were made to the Materials and Methods to better indicate the protein concentrations used: “Beads were incubated with ~8 µg protein or 6–10 µl (~1 µg/µl) at a final concentration of ~80 ng/µl of extract (unless a range of extract concentrations is specified)”

6.) “The section titled “Pharmacological inhibition of CKIe/d” also includes details of preparation of cell extracts, which might fit more logically as a separate section following preparation of tissue extracts.”
Answer: A separate section describing the preparation of cell extracts has been added to Materials and Methods.

7.) “Related to point #5 above, there is no mention of the concentration of extract used in experiments shown in Fig. 1. What does arbitrary units refer to on the x and y axes in Fig. 1B? In Fig. 1E and Fig. 4C, the x axis is labeled “fold dilution” or “l extract” but it would be much more informative to know what concentration of extract is included in the assay.”

Answer: As noted above in the answer to point #5, a better description of the protein concentrations of extracts used in all assays, unless a concentration series is stated, has been added to Materials and Methods. In addition, the concentration equivalent to 1 in Figure 1E is now noted in the legend: “1 = 16 µg of extract or 160 ng/µl final extract concentration with magnetic beads.” In Figure 1B, AU in the x-axis is a typo and has been changed (x-axis in this case is ul of magnetic beads, as noted in the legend). Y-axis AUs are raw luminescence counts from a plate reader.

8.) “In Figs 3A and 3D, the legend refers to Western blot detection of PER2 and CKId that does not appear in the figure.”

Answer: This was a typo and has been corrected.

9.) “The text states that there are similar levels of CLOCK and BMAL1 protein in each condition in Fig 3D but the figure shows much less CLOCK and BMAL1 protein in the extract treated with PF671462. Both Fig. 3A and 3D should include a loading control blot as well. Since the change in protein amounts appears to be opposite to the change in binding measured, this does not invalidate the conclusions but the data should be described accurately in the text.”

Answer: Please see revised Results section addressing the description of the data: “Whole cell extracts were analyzed by SDS-PAGE/immunoblotting for CLOCK and BMAL1 indicating similar or lower levels (as shown) of CLOCK and BMAL1 in the PF670462 treated condition (Figure 3D/Uncropped Figure 3B)...” Also, to Figures 3A and 3D we have added portions of SDS-PAGE/coomassie stained gels which we believe are equal or better than western blot controls to assess equal loading.

Best Regards

**Competing Interests:** No competing interests were disclosed.

doi:10.5256/f1000research.12624.r24786

Yoshitaka Fukada ¹, Naohiro Kon ²

¹ Department of Biological Sciences, School of Science, University of Tokyo, Tokyo, Japan
² Medical Science Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan
In the present work, the authors developed a novel method to detect DNA binding activity of CLOCK-BMAL1 complex with a fixed DNA probe containing an E-Box repeat. The method is based on a simple procedure and could be useful for studies including high-throughput investigation of the regulatory mechanism on CLOCK-BMAL1.

It is desirable to compare the new method with previously established ones, e.g., EMSA and ChIP-PCR in parallel experiments by using the same samples. Then, readers could easily understand advantage/disadvantage of the present assay, in terms of detection limit, the range, and sensitivity etc.

The data in Figure 3 demonstrate enhanced DNA-binding activities of CLOCK:BMAL1 by pre-treatment with lambda phosphatase and CKI-epsilon/delta inhibitor (PF670462). We are interested in a potential change of the CLOCK-BMAL1 activity under previously described conditions. For example, we reported several treatments that reduce the transactivation ability of CLOCK-BMAL1 complex: MAPK-dependent phosphorylation of BMAL1, phospho-mimic mutation in CLOCK, reduced CLOCK-BMAL1 dimerization under CaMKII inhibition [1,2,3]

**References**


**Is the rationale for developing the new method (or application) clearly explained?**
Yes

**Is the description of the method technically sound?**
Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**
Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**
Partly

**Competing Interests:** No competing interests were disclosed.
We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 08 Sep 2017

Alfred Tamayo, Harvard Medical School, USA

Dear Dr. Fukada and Dr. Kon. A new version of this manuscript has been submitted with the changes indicated below.

1.) “It is desirable to compare the new method with previously established ones, e.g., EMSA and ChIP-PCR in parallel experiments by using the same samples. Then, readers could easily understand advantage/disadvantage of the present assay, in terms of detection limit, the range, and sensitivity etc.”

Answer: While it is beyond the scope of this work to perform parallel experiments with other techniques, we comment on their comparison in our revised Discussion section: “In addition, we show that the CPDBA can be adapted to quantify CLOCK-BMAL1 binding to reconstituted chromatin, in the form of mononucleosomes. This variation of the CPDBA could be used to provide in vivo ChIP studies with mechanistic insights. … We also performed related experiments using an electrophoretic mobility shift assays (EMSA) to monitor the effect of phosphatase on purified nuclear PER complex (containing CLOCK-BMAL1), and we again detected an increase in DNA binding upon phosphatase treatment (Aryal and Kwak et al., 2017). EMSA may surpass the CPDBA in sensitivity and detection limit, since it can use radiolabeled DNA probes to quantify protein-DNA binding. However, the CPDBA is less technically cumbersome and more scalable than EMSAs.”

2.) “The data in Figure 3 demonstrate enhanced DNA-binding activities of CLOCK:BMAL1 by pre-treatment with lambda phosphatase and CKI-epsilon/delta inhibitor (PF670462). We are interested in a potential change of the CLOCK-BMAL1 activity under previously described conditions. For example, we reported several treatments that reduce the transactivation ability of CLOCK-BMAL1 complex: MAPK-dependent phosphorylation of BMAL1, phospho-mimic mutation in CLOCK, reduced CLOCK-BMAL1 dimerization under CaMKII inhibition [1,2,3].”

Answer: The complex relationship between phosphorylation and CLOCK-BMAL1 regulation is indeed interesting and requires a comprehensive understanding of the causal relationship between site-specific phosphorylation, biochemical activity and biological consequence. As you point out, it would be interesting to interrogate the roles of other kinases, such as MAPKs and CaMKII in CLOCK-BMAL1 DNA binding using the CPDBA. We should note that dose and exposure time would need to be optimized in any kinase inhibitor study, as was done for PF670462, though we do not mention it in the manuscript. We must also point out however that this assay cannot assess CLOCK-BMAL1 transactivation activity downstream of DNA binding.

Also, we have changed how your work is cited in the Results section to better distinguish it from the other works cited.

Best Regards

Competing Interests: No competing interests were disclosed.